Literature DB >> 21132379

A role for epidermal growth factor receptor in idiopathic pulmonary fibrosis onset.

Marcella Martinelli1, Angela Maria Grazia Pacilli, Stefano Rivetti, Mattia Lauriola, Luca Fasano, Paolo Carbonara, Gabriella Mattei, Ilaria Valentini, Luca Scapoli, Rossella Solmi.   

Abstract

In idiopathic pulmonary fibrosis (IPF) patients the presence of missense polymorphisms (SNP) in members of the epidermal growth factor receptor (EGFR) family or their genetic association could influence the binding affinity of natural ligands, modifying the expression and the behavior of the correlated genes. EGFR family members are particularly involved in the epithelial injury and fibrotic process in IPF. Genetic variations in HER family of receptors may alter the possible therapeutic efficacy of EGFR inhibitors. This study aimed to analyze the relationships between IPF and specific EGF receptor family functional polymorphisms. We tested the presence of common EGFR, HER2 and HER3 non-synonymous SNPs in the peripheral blood of 20 Italian IPF patients and their association with the disease. Our data indicated that the HER2 variant allele frequency was significantly lower in patients than in controls, with an odds ratio of 0.31 (95% CI 0.080, 0.98). Our finding suggests that HER2 variant could be a protective factor against IPF onset.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21132379     DOI: 10.1007/s11033-010-0594-0

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  28 in total

1.  Distribution of epidermal growth factor receptor and ligands during bronchiolar epithelial repair from naphthalene-induced Clara cell injury in the mouse.

Authors:  L S Van Winkle; J M Isaac; C G Plopper
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

2.  Biology of fibroblasts and myofibroblasts.

Authors:  Sem H Phan
Journal:  Proc Am Thorac Soc       Date:  2008-04-15

3.  Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix.

Authors:  Kevin K Kim; Matthias C Kugler; Paul J Wolters; Liliane Robillard; Michael G Galvez; Alexis N Brumwell; Dean Sheppard; Harold A Chapman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-21       Impact factor: 11.205

4.  Gefitinib prevents bleomycin-induced lung fibrosis in mice.

Authors:  Yoshiki Ishii; Sakae Fujimoto; Takeshi Fukuda
Journal:  Am J Respir Crit Care Med       Date:  2006-06-01       Impact factor: 21.405

Review 5.  High-resolution computed tomography in the diagnosis and follow-up of idiopathic pulmonary fibrosis.

Authors:  N Sverzellati; M De Filippo; T Bartalena; S Piciucchi; M Zompatori
Journal:  Radiol Med       Date:  2010-01-15       Impact factor: 3.469

6.  Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.

Authors:  Gabriele Schaefer; Lihua Shao; Klara Totpal; Robert W Akita
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

Review 7.  Strategies for treating idiopathic pulmonary fibrosis.

Authors:  R M du Bois
Journal:  Nat Rev Drug Discov       Date:  2010-01-22       Impact factor: 84.694

8.  EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis.

Authors:  William D Hardie; Cynthia Davidson; Machiko Ikegami; George D Leikauf; Timothy D Le Cras; Adrienne Prestridge; Jeffrey A Whitsett; Thomas R Korfhagen
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-04-18       Impact factor: 5.464

9.  Bleomycin-induced pulmonary fibrosis is attenuated by a monoclonal antibody targeting HER2.

Authors:  Jihane A Faress; David E Nethery; Elizabeth F O Kern; Rosana Eisenberg; Frank J Jacono; Chris L Allen; Jeffrey A Kern
Journal:  J Appl Physiol (1985)       Date:  2007-10-04

10.  Fibrotic myofibroblasts manifest genome-wide derangements of translational control.

Authors:  Ola Larsson; Deanna Diebold; Danhua Fan; Mark Peterson; Richard Seonghun Nho; Peter B Bitterman; Craig A Henke
Journal:  PLoS One       Date:  2008-09-16       Impact factor: 3.240

View more
  8 in total

1.  Selenium supplementation prevents metabolic and transcriptomic responses to cadmium in mouse lung.

Authors:  Xin Hu; Joshua D Chandler; Jolyn Fernandes; Michael L Orr; Li Hao; Karan Uppal; David C Neujahr; Dean P Jones; Young-Mi Go
Journal:  Biochim Biophys Acta Gen Subj       Date:  2018-04-12       Impact factor: 3.770

2.  BMP-7 attenuates liver fibrosis via regulation of epidermal growth factor receptor.

Authors:  Li-Ping Wang; Jin-Zhong Dong; Li-Jun Xiong; Ke-Qing Shi; Zhuo-Lin Zou; Sai-Nan Zhang; Su-Ting Cao; Zhuo Lin; Yong-Ping Chen
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  Soluble ECM promotes organotypic formation in lung alveolar model.

Authors:  Jonard C Valdoz; Nicholas A Franks; Collin G Cribbs; Dallin J Jacobs; Ethan L Dodson; Connor J Knight; P Daniel Poulson; Seth R Garfield; Benjamin C Johnson; Brandon M Hemeyer; Miranda T Sudo; Jordan A Saunooke; Braden C Kartchner; Aubrianna Saxton; Mary L Vallecillo-Zuniga; Matheus Santos; Brandon Chamberlain; Kenneth A Christensen; Greg P Nordin; A Sampath Narayanan; Ganesh Raghu; Pam M Van Ry
Journal:  Biomaterials       Date:  2022-03-16       Impact factor: 15.304

Review 4.  Biomarkers in idiopathic pulmonary fibrosis.

Authors:  Yingze Zhang; Naftali Kaminski
Journal:  Curr Opin Pulm Med       Date:  2012-09       Impact factor: 3.155

5.  Bone Marrow CD11c+ Cell-Derived Amphiregulin Promotes Pulmonary Fibrosis.

Authors:  Lin Ding; Tianju Liu; Zhe Wu; Biao Hu; Taku Nakashima; Matthew Ullenbruch; Francina Gonzalez De Los Santos; Sem H Phan
Journal:  J Immunol       Date:  2016-05-20       Impact factor: 5.422

Review 6.  Personalized medicine: applying 'omics' to lung fibrosis.

Authors:  Jose D Herazo-Maya; Naftali Kaminski
Journal:  Biomark Med       Date:  2012-08       Impact factor: 2.851

7.  Amphiregulin, an epidermal growth factor receptor ligand, plays an essential role in the pathogenesis of transforming growth factor-β-induced pulmonary fibrosis.

Authors:  Yang Zhou; Jae-Young Lee; Chang-Min Lee; Won-Kyung Cho; Min-Jong Kang; Jonathan L Koff; Pyeong-Oh Yoon; Jeiwook Chae; Han-Oh Park; Jack A Elias; Chun Geun Lee
Journal:  J Biol Chem       Date:  2012-10-19       Impact factor: 5.157

8.  Gefitinib Inhibits Bleomycin-Induced Pulmonary Fibrosis via Alleviating the Oxidative Damage in Mice.

Authors:  Li Li; Lin Cai; Linxin Zheng; Yujie Hu; Weifeng Yuan; Zhenhui Guo; Weifeng Li
Journal:  Oxid Med Cell Longev       Date:  2018-04-12       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.